Last reviewed · How we verify
NCT00646126
Validation of the Use of Istope-Based Molecular Techniques for Malaria Control
Phase 3 trial testing Sulfadoxine / Pyrimethamine (SP) plus artesunate (AS) in Plasmodium Falciparum. Completed.
Quick facts
| Lead sponsor | Tropical Medicine Research Institute |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Start date | 1 August 2005 |
| Sites | 1 location across Sudan |
Drugs / interventions tested
- Sulfadoxine / Pyrimethamine (SP) plus artesunate (AS) — full drug profile →
- placebo tablet similar to active drug in shape and size — full drug profile →
Conditions studied
- Plasmodium Falciparum — all drugs for Plasmodium Falciparum →
- Asymptomatic Parataemia — all drugs for Asymptomatic Parataemia →
- Sub Patent Parasitaemia — all drugs for Sub Patent Parasitaemia →
Sponsor
Tropical Medicine Research Institute
Who can join
1 and older, any sex, with Plasmodium Falciparum or Asymptomatic Parataemia. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Parsitaemia detected during the transmission season among dry season PCR negative persons in the intervention and control villages
Time frame: October to December 2006
Sponsor's own description
The malaria parasite Plasmodium falciparum remains at sub-patent level throughout the dry season in areas of seasonal malaria transmission. Targeting this parasite reservoir before the transmission season could be a good strategy for malaria control. We are conducting a randomized double blind placebo controlled mass drug administration trial in eight village to clear the dry season low level parasitaemia with an ultimate aim of controlling malaria in eastern Sudan.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Mass drug administration for malaria.
Shah MP, Hwang J, Choi L, Lindblade KA, et al · · 2021 · cited 31× · PMID 34585740 · DOI 10.1002/14651858.cd008846.pub3
Verify or expand the search:
- PubMed search for NCT00646126
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Plasmodium Falciparum
Currently open trials in the same condition.
- NCT06923592 — Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00646126 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tropical Medicine Research Institute
- Last refreshed: 27 March 2008
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00646126.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing